@article{27cd791fdf8e4a5e8a563ae627c74894,
title = "2017 HIV Medicine Association of Infectious Diseases Society of America Clinical Practice Guideline for the Management of Chronic Pain in Patients Living with Human Immunodeficiency Virus",
abstract = "Pain has always been an important part of human immunodeficiency virus (HIV) disease and its experience for patients. In this guideline, we review the types of chronic pain commonly seen among persons living with HIV (PLWH) and review the limited evidence base for treatment of chronic noncancer pain in this population. We also review the management of chronic pain in special populations of PLWH, including persons with substance use and mental health disorders. Finally, a general review of possible pharmacokinetic interactions is included to assist the HIV clinician in the treatment of chronic pain in this population. It is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. The Infectious Diseases Society of American considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances.",
author = "Bruce, {R. Douglas} and Jessica Merlin and Lum, {Paula J.} and Ebtesam Ahmed and Carla Alexander and Corbett, {Amanda H.} and Kathleen Foley and Kate Leonard and Treisman, {Glenn Jordan} and Peter Selwyn",
note = "Funding Information: Acknowledgments. The Expert Panel expresses its gratitude to external reviewers Drs Robert Arnold, E. Jennifer Edelman, and Romy Parker. The panel also thanks Vita Washington for continued guidance throughout the guideline development process. Financial support. Support was provided by the Infectious Diseases Society of America (IDSA). Potential conflicts of interest. The following is a reflection of what has been reported to the IDSA. In order to provide thorough transparency, the IDSA requires full disclosure of all relationships, regardless of relevancy to the guideline topic. Evaluation of such relationships as potential conflicts of interest is determined by a review process that includes assessment by the Standards and Practice Guidelines Committee (SPGC) chair, the SPGC liaison to the development panel, the Board of Directors (BOD) liaison to the SPGC, and, if necessary, the Conflict of Interest Task Force of the board. This assessment of disclosed relationships for possible conflicts of interest is based on the relative weight of the financial relationship (ie, monetary amount) and the relevance of the relationship (ie, the degree to which an association might reasonably be interpreted by an independent observer as related to the topic or recommendation of consideration). The reader should be mindful of this when the list of disclosures is reviewed. A. C. has received research grants from the Centers for Disease Control and Prevention and National Institutes of Health. All remaining authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. Publisher Copyright: {\textcopyright} The Author 2017.",
year = "2017",
month = nov,
day = "15",
doi = "10.1093/cid/cix848",
language = "English (US)",
volume = "65",
pages = "1601--1606",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "10",
}